Articles
3 June 2009
Vol. 1 No. 9: 3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, October 14-16, 2005
https://doi.org/10.4081/hmr.v1i9.322

Future perspective of clinical trials of antithrombotics and cancer survival

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
152
Views
180
Downloads

Authors

R Er
support@pagepress.org
One of the most exciting issue related to anticoagulant therapy is its potential for an antineoplastic effect. The notion that anticoagulants have an antineoplastic effect is provocative. A strong association between cancer and thrombosis has been demonstrated consistently in experimental and clinical studies. Randomized controlled trials and meta-analyses of studies that compared low molecular weight heparins (LMWH) with unfractionated heparin for the initial treatment of venous thromboembolism have reported a reduction in the overall mortality of patients with cancer who were randomly assigned to receive a LMWH.1

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Future perspective of clinical trials of antithrombotics and cancer survival. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.322